CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 80 enrolled
Drug / intervention
Regadenoson +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01919450
NCT01919450Phase 4Completed
CompareCT.gov

Characterization of Myocardial Blood Flow Measurements Using Lexiscan®™ (Regadenoson) (Lexiscan®™) Rubidium-82 Myocardial Perfusion PET: A Temporal-Dependency Investigation

Timothy M. Bateman, MD·interventional·Posted Aug 9, 2013·Updated Aug 16, 2018

In Brief

A Phase 4 clinical trial evaluating Regadenoson and Rubidium-82 for Myocardial Blood Flow Reserve. Completed, enrolled 80 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate the consistency of quantitative peak stress myocardial blood flow and myocardial blood flow reserve following a 10 second, 1 minute, 2 minute or 4 minute delay in beginning the rubidium-82 infusion post-Lexiscan (regadenoson) injection. It is anticipated that there will be no or minimal difference between the four delay times.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMyocardial Blood Flow Reserve
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedAug 9, 2013
Enrollment StartJul 1, 2013
Primary CompletionApr 1, 2016
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 12.9 years ago

Interventions

Regadenosondrug

Subjects will undergo a rest/Lexiscan (regadenoson) stress myocardial perfusion PET study.

Rubidium-82radiation

Subjects undergo a rest/Lexiscan (regadenoson) stress myocardial perfusion PET study.